Professor Mark Gorrell heads the Liver Enzymes in Metabolism and Inflammation Program. He trained in cell biology, virology, immunology and protein biochemistry at the Australian National University and University of Melbourne in Australia, and at Johns Hopkins University in the USA.
His research is focussed upon liver scarring and cancer prevention and treatment, chronic liver disease pathogenesis, diabetes, protein and enzyme biochemistry and cell biology related to the proteases DPP4, DPP9 and fibroblast activation protein (FAP).
He has authored over 184 publications attracting H index 55, and > 11,000 citations. His research was important in the development of DPP4-targeted therapies for type 2 diabetes, which are now used to treat millions of patients. His research experience also includes protein biochemistry, small RNA viruses, transcriptomics, proteomics and cell biology.
Professor Gorrell has supervised more than 21 PhD and M Phil students. He is active in the International Proteolysis Society, the Gastroenterological Society of Australia, NHMRC grant reviews, and is an editorial board member for Cancers and for Scientific Reports.
